Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C78H105ClN18O13.2C2H4O2 |
Molecular Weight | 1658.338 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O.CC(O)=O.CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@@H](CC4=CC=C(Cl)C=C4)NC(=O)[C@@H](CC5=CC6=C(C=CC=C6)C=C5)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N7CCC[C@H]7C(=O)N[C@H](C)C(N)=O
InChI
InChIKey=JJGCQOXTSHXMKH-ZJURQMCGSA-N
InChI=1S/C78H105ClN18O13.2C2H4O2/c1-7-83-78(84-8-2)86-34-14-13-21-58(68(102)92-60(37-45(3)4)69(103)91-59(22-15-35-85-77(81)82)76(110)97-36-16-23-66(97)75(109)88-46(5)67(80)101)90-71(105)62(40-49-27-32-55(100)33-28-49)94-74(108)65(44-98)96-73(107)64(42-53-43-87-57-20-12-11-19-56(53)57)95-72(106)63(39-48-25-30-54(79)31-26-48)93-70(104)61(89-47(6)99)41-50-24-29-51-17-9-10-18-52(51)38-50;2*1-2(3)4/h9-12,17-20,24-33,38,43,45-46,58-66,87,98,100H,7-8,13-16,21-23,34-37,39-42,44H2,1-6H3,(H2,80,101)(H,88,109)(H,89,99)(H,90,105)(H,91,103)(H,92,102)(H,93,104)(H,94,108)(H,95,106)(H,96,107)(H4,81,82,85)(H2,83,84,86);2*1H3,(H,3,4)/t46-,58-,59+,60+,61-,62+,63-,64-,65+,66+;;/m1../s1
Molecular Formula | C78H105ClN18O13 |
Molecular Weight | 1538.234 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 3 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C2H4O2 |
Molecular Weight | 60.052 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Detirelix is a synthetic decapeptide containing five D-amino acids. It is a very potent Gonadotropin-releasing hormone (GnHR) antagonist. The acute effects of detirelix were consistent with peripheral vasodilation. Subchronic effects were associated with inhibition of pituitary gonadotropic and gonadal hormone secretion. As long-acting GnRH antagonist detirelix can rapidly suppress gonadotropin secretion, inhibit follicular development, and prevent ovulation. It can be used as luteolytic agent. A projected use is for the treatment of sex hormone-releasing diseases, as part of anticancer hormone therapy of sex-hormone-dependent tumors.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:48:56 GMT 2023
by
admin
on
Sat Dec 16 07:48:56 GMT 2023
|
Record UNII |
V81F7B15KR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
102583-46-0
Created by
admin on Sat Dec 16 07:48:56 GMT 2023 , Edited by admin on Sat Dec 16 07:48:56 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106408
Created by
admin on Sat Dec 16 07:48:56 GMT 2023 , Edited by admin on Sat Dec 16 07:48:56 GMT 2023
|
PRIMARY | |||
|
119307-68-5
Created by
admin on Sat Dec 16 07:48:56 GMT 2023 , Edited by admin on Sat Dec 16 07:48:56 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
16137391
Created by
admin on Sat Dec 16 07:48:56 GMT 2023 , Edited by admin on Sat Dec 16 07:48:56 GMT 2023
|
PRIMARY | |||
|
DTXSID10145294
Created by
admin on Sat Dec 16 07:48:56 GMT 2023 , Edited by admin on Sat Dec 16 07:48:56 GMT 2023
|
PRIMARY | |||
|
X-10
Created by
admin on Sat Dec 16 07:48:56 GMT 2023 , Edited by admin on Sat Dec 16 07:48:56 GMT 2023
|
PRIMARY | |||
|
C169889
Created by
admin on Sat Dec 16 07:48:56 GMT 2023 , Edited by admin on Sat Dec 16 07:48:56 GMT 2023
|
PRIMARY | |||
|
V81F7B15KR
Created by
admin on Sat Dec 16 07:48:56 GMT 2023 , Edited by admin on Sat Dec 16 07:48:56 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |